January of 2024, Fuent (Qurgen’s China subsidiary) officially started the operations at Qurgen’s first GMP manufacturing facility located in Suzhou High-tech Zone, China. In July of 2025, the facility has successfully completed four batches of SON-DP anti-cancer transcription factor protein drug which all meet the FDA/NMPA protein drug quality standards. The GMP-manufactured SON-DP has been used in both Qurgen’s US ongoing trial and Fuent’s ongoing China clinical trial.
